General description
Ifosfamide is a nitrogen mustard alkylating agent used in treatment protocols for bone and soft tissue sarcomas, and testicular and ovarian cancers.
INN
Ifosfamide
ATC codes
Medicine type
Chemical agent
EML status history
First added in 2009
(TRS
958)
for
Other specified malignant neoplasms of the ovary
Added in 2009
(TRS
958)
for
Ewing sarcoma of bone and articular cartilage of unspecified sites
Added in 2009
(TRS
958)
for
Rhabdomyosarcoma primary site
Added in 2009
(TRS
958)
for
Osteosarcoma of bone and articular cartilage of unspecified sites
Added in 2009
(TRS
958)
for
Germ cell tumour of testis
Added in 2009
(TRS
958)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2021
(TRS
1035)
for
Burkitt lymphoma including Burkitt leukaemia
Added in 2021
(TRS
1035)
for
Malignant neoplasms of kidney, except renal pelvis
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-positive
Added in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-negative
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
Indications
Osteosarcoma of bone and articular cartilage of unspecified sites
Other specified malignant neoplasms of the ovary
Germ cell tumour of testis
Rhabdomyosarcoma primary site
Ewing sarcoma of bone and articular cartilage of unspecified sites
Unspecified malignant neoplasms of ill-defined or unspecified sites
Burkitt lymphoma including Burkitt leukaemia
Malignant neoplasms of kidney, except renal pelvis
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative